NO964802L - DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav - Google Patents

DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav

Info

Publication number
NO964802L
NO964802L NO964802A NO964802A NO964802L NO 964802 L NO964802 L NO 964802L NO 964802 A NO964802 A NO 964802A NO 964802 A NO964802 A NO 964802A NO 964802 L NO964802 L NO 964802L
Authority
NO
Norway
Prior art keywords
applications
homologous recombination
dna constructs
efficient homologous
efficient
Prior art date
Application number
NO964802A
Other languages
English (en)
Other versions
NO964802D0 (no
Inventor
Douglas A Treco
Michael W Heartlein
Richard F Selden
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22918596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO964802(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of NO964802D0 publication Critical patent/NO964802D0/no
Publication of NO964802L publication Critical patent/NO964802L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO964802A 1994-05-13 1996-11-12 DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav NO964802L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/243,391 US5641670A (en) 1991-11-05 1994-05-13 Protein production and protein delivery
PCT/US1995/006045 WO1995031560A1 (en) 1994-05-13 1995-05-11 Dna construct for effecting homologous recombination and uses thereof

Publications (2)

Publication Number Publication Date
NO964802D0 NO964802D0 (no) 1996-11-12
NO964802L true NO964802L (no) 1997-01-09

Family

ID=22918596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964802A NO964802L (no) 1994-05-13 1996-11-12 DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav

Country Status (19)

Country Link
US (1) US5641670A (no)
EP (1) EP0759082A1 (no)
JP (1) JPH10500570A (no)
KR (1) KR100379356B1 (no)
AU (1) AU709058B2 (no)
BR (1) BR9507874A (no)
CA (1) CA2190289A1 (no)
CZ (1) CZ295115B6 (no)
FI (1) FI964536A (no)
HU (1) HUT76844A (no)
IL (1) IL113708A0 (no)
MX (1) MX9605542A (no)
NO (1) NO964802L (no)
NZ (1) NZ285945A (no)
RU (1) RU2267533C2 (no)
SK (1) SK146196A3 (no)
UA (1) UA34493C2 (no)
WO (1) WO1995031560A1 (no)
ZA (1) ZA953879B (no)

Families Citing this family (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
JP2657113B2 (ja) * 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5981730A (en) * 1994-04-13 1999-11-09 The General Hospital Corporation RPS gene family, primers, probes, and detection methods
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU4085297A (en) * 1996-08-23 1998-03-06 Chiron Corporation Human polyhomeotic 1(hphl) acts as a tumor suppressor
KR100547402B1 (ko) 1996-09-13 2006-02-01 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
AU4424597A (en) * 1996-09-13 1998-04-02 Novo Nordisk Biotech, Inc. Cells having dna insertion mutations which produce altered amounts of a polypeptide
CA2267664C (en) 1996-10-01 2013-06-11 Geron Corporation Human telomerase reverse transcriptase
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
JP2001505783A (ja) * 1996-12-11 2001-05-08 カイロン コーポレイション 分泌ヒトタンパク質
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
DK0981630T3 (da) 1997-05-16 2009-03-09 Novozymes Inc Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
PT1000154E (pt) * 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes
DK0986644T3 (da) * 1997-07-23 2007-01-29 Roche Diagnostics Gmbh Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer
US6395484B1 (en) * 1997-07-23 2002-05-28 Roche Diagnostics Gmbh Identification of human cell lines for the production of human proteins by endogenous gene activation
KR100641969B1 (ko) * 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법
AU776280B2 (en) * 1997-07-23 2004-09-02 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
CN101348789B (zh) * 1997-07-23 2016-08-17 罗切诊断学有限公司 通过同源重组在人细胞中生产人突变蛋白
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US7316923B1 (en) 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
BR9812540A (pt) * 1997-09-26 2001-12-26 Athersys Inc Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular
ZA989497B (en) * 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
CA2309810C (en) * 1997-12-03 2014-07-08 Roche Diagnostics Gmbh Erythropoietin with high specific activity
US7037663B2 (en) * 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
WO1999042581A1 (en) 1998-02-19 1999-08-26 Eastern Virginia Medical School RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6808921B1 (en) * 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
IL139433A0 (en) * 1998-05-07 2001-11-25 Transkaryotic Therapies Inc Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery
HUP0101355A3 (en) * 1998-05-07 2003-08-28 Transkaryotic Therapies Inc Ca Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
RU2229309C2 (ru) * 1998-05-07 2004-05-27 Транскариотик Терапиз, Инк. МОДИФИЦИРОВАНИЕ ЭКСПРЕССИИ ГЕНА FSHβ С ПОМОЩЬЮ ГОМОЛОГИЧНОЙ РЕКОМБИНАЦИИ
AU4213999A (en) * 1998-05-27 1999-12-13 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide by modifying the copy number of a gene
MXPA01000830A (es) 1998-07-21 2002-06-04 Cobra Therapeutics Ltd Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina.
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
DE69938190T2 (de) 1998-10-15 2009-03-05 Novartis Vaccines and Diagnostics, Inc., Emeryville Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
US6416975B1 (en) 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
ES2312223T3 (es) 1998-12-07 2009-02-16 Zymogenetics, Inc. Zvegf3 homologo de factor de crecimiento.
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
ATE408695T1 (de) 1998-12-16 2008-10-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
AU3003700A (en) * 1999-02-19 2000-09-04 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000053761A2 (en) 1999-03-09 2000-09-14 Zymogenetics, Inc. Human cytokine as ligand of the zalpha receptor and uses thereof
JP4620253B2 (ja) 1999-03-22 2011-01-26 ノボザイムス，インコーポレイティド 菌類細胞中で遺伝子を発現させるためのプロモーター
CA2369262A1 (en) 1999-04-13 2000-10-19 Sudha Nagarajan Pulmonary administration of dry powder formulations for treating infertility
CA2376487A1 (en) * 1999-06-15 2000-12-21 Allan S. Lau Methods for enhancing the production of cytokines in cell culture
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
EP2275559A3 (en) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
EP1305412A2 (en) 1999-10-14 2003-05-02 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
IL149679A0 (en) * 1999-11-19 2002-11-10 Transkaryotic Therapies Inc Nucleic acid construct and methods utilizing the same
ATE435871T1 (de) 1999-11-22 2009-07-15 Zymogenetics Inc Methode zur bildung einen peptid-rezeptor komplex mit zsig33 polypeptiden.
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
WO2001042442A2 (en) * 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
EP2194130A1 (en) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Cytokine ZCYTO18
US7605246B2 (en) 2000-01-10 2009-10-20 Novartis Vaccines And Diagnostics, Inc. Genes differentially expressed in breast cancer
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US6569681B1 (en) * 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU8847801A (en) 2000-08-25 2002-03-04 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
WO2002045720A1 (en) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
KR100645843B1 (ko) * 2000-12-20 2006-11-14 에프. 호프만-라 로슈 아게 에리트로포이에틴 접합체
WO2002049673A2 (en) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
ATE434936T1 (de) 2001-03-14 2009-07-15 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303262A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
US7262174B2 (en) * 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
WO2003001876A2 (en) 2001-06-26 2003-01-09 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
AU2002318229B2 (en) 2001-07-10 2008-03-13 Senomyx, Inc. Use of specific T2R taste receptors to identify compounds that block bitter taste
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2456821A1 (en) * 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
CA2456571A1 (en) * 2001-08-10 2003-02-20 Genset Sa Human secreted proteins, their encoding polynucleotides, and uses thereof
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
EP1453854A2 (en) * 2001-11-28 2004-09-08 Genset S.A. Human cdnas and proteins and uses thereof
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
JP4700281B2 (ja) * 2001-12-19 2011-06-15 ザ・ユニバーシティ・オブ・シカゴ 急速に成熟する蛍光タンパク質およびその使用法
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
DK2230299T3 (da) 2002-01-18 2012-03-26 Zymogenetics Inc Hidtil ukendt cytokin ZCYTOR17-ligand
WO2003066085A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
WO2003069984A2 (en) 2002-02-20 2003-08-28 American Integrated Biologics, Inc. Transgenic production in saliva
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2003215869B2 (en) * 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
WO2003089617A2 (en) 2002-04-22 2003-10-30 Novozymes Biotech, Inc. Methods for increasing homologous recombination of a nucleic acid sequence
WO2003090695A2 (en) 2002-04-25 2003-11-06 Transkaryotic Therapies, Inc. TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1585822B1 (en) 2002-11-18 2012-01-25 Novozymes, Inc. Promoter variants for expressing genes in a fungal cell
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP1897959A1 (en) * 2002-11-22 2008-03-12 The Johns Hopkins University Target for therapy of cognitive impairment
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
WO2004053144A2 (en) * 2002-12-10 2004-06-24 Ottawa Health Research Institute Modulation of stem cell differentiation by modulation of caspase-3 activity
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
EP1594433B8 (en) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Cancer therapy sensitizer
WO2004065551A2 (en) * 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
NZ603330A (en) 2003-02-11 2015-02-27 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
NZ544335A (en) * 2003-06-11 2009-01-31 Biogen Idec Inc Method to increase protein production in culture
CN103275058B (zh) 2003-08-06 2016-02-24 西诺米克斯公司 调味剂、味道调节剂、促味剂、味觉增强剂、鲜味剂或甜味剂和/或增强剂及其用途
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
JP2007507224A (ja) * 2003-09-30 2007-03-29 レキシコン ジェネティックス インコーポレーテッド 遺伝子の機能を定義するための方法および組成物
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
CA2546760C (en) 2003-11-20 2015-01-06 Songtao Shi Multipotent postnatal stem cells from human periodontal ligament and uses thereof
AU2004295171A1 (en) * 2003-12-03 2005-06-16 Novozymes Biopharma Dk A/S Interleukin-11 fusion proteins
ES2460671T3 (es) * 2003-12-19 2014-05-14 F. Hoffmann-La Roche Ag Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
MXPA06008126A (es) * 2004-01-14 2008-02-14 Univ Ohio Metodos para la produccion de peptidos/proteinas en plantas y peptidos/proteinas producidos de este modo.
EP1732944B1 (en) * 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
EP1751177A4 (en) 2004-04-19 2008-07-16 Univ Ohio NETWORKABLE GLYCOPROTEINS AND METHOD FOR THEIR PRODUCTION
AU2005249434A1 (en) * 2004-05-26 2005-12-15 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting mage gene expression or function
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
CA2579677A1 (en) * 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20060147443A1 (en) * 2004-12-22 2006-07-06 Kuros Biosurgery Ag Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages
EP2298889A1 (en) 2004-12-30 2011-03-23 Agency for Science, Technology and Research Chinese hamster apoptosis-related genes
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
ES2902872T3 (es) * 2005-01-06 2022-03-30 Kuros Biosurgery Ag Matrices suplementadas para la reparación de fracturas óseas
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006086639A1 (en) 2005-02-10 2006-08-17 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US20070011752A1 (en) * 2005-05-06 2007-01-11 American Integrated Biologics, Inc. Production of human proteins in transgenic animal saliva
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
WO2007005955A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
EP1904652A2 (en) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US20100040636A1 (en) 2005-09-09 2010-02-18 The Johns Hopkins University Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
AU2006311827A1 (en) 2005-11-03 2007-05-18 Redpoint Bio Corporation High throughput screening assay for the TRPM5 ion channel
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
JP5364382B2 (ja) 2006-02-07 2013-12-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
WO2007100870A2 (en) 2006-02-28 2007-09-07 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
EP2004683B1 (en) * 2006-03-24 2016-05-11 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
EP3235811B1 (en) 2006-04-21 2018-07-25 Senomyx, Inc. Process of preparing oxalamides
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
EP2054074B8 (en) 2006-08-04 2014-11-12 Prolong Pharmaceuticals, LLC Modified erythropoietin
EP2054437A2 (en) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
WO2008116116A2 (en) * 2007-03-20 2008-09-25 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
JP2010523243A (ja) * 2007-04-13 2010-07-15 クロス・バイオサージェリー・アクチェンゲゼルシャフト 高分子組織シーラント
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
WO2009015063A2 (en) 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
EP2195656A4 (en) 2007-08-21 2011-10-19 Senomyx Inc HUMAN T2R BITTERITY RECEPTORS AND USES THEREOF
WO2009059305A2 (en) * 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
WO2009073511A2 (en) * 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
JP2012512812A (ja) * 2007-12-28 2012-06-07 クロス・バイオサージェリー・アクチェンゲゼルシャフト フィブリンフォームに組込まれたｐｄｇｆ融合タンパク質
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
CA2725208A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
KR101781907B1 (ko) 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2453856B1 (en) 2009-07-15 2019-02-20 NewSouth Innovations Pty Limited Agent provided to the cochlea and cochlear implant
MX2012001268A (es) 2009-07-28 2012-09-12 Shire Human Genetic Therapies Composiciones y metodos para tratar enfermedad de gaucher.
PL3482767T3 (pl) 2009-08-28 2022-02-14 Icahn School Of Medicine At Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
JP5735650B2 (ja) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｅｇ化エリスロポエチンを精製するための方法
PL2635299T3 (pl) 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
CN105420267A (zh) 2010-11-30 2016-03-23 诺维信股份有限公司 用于在真菌细胞中表达基因的启动子
US9862928B2 (en) 2010-12-03 2018-01-09 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
WO2012078712A2 (en) 2010-12-07 2012-06-14 Vnomics Corp. System and method for measuring and reducing vehicle fuel waste
US9284588B2 (en) 2010-12-16 2016-03-15 Novozymes, Inc. Promoters for expressing genes in a fungal cell
EP3153583B1 (en) 2010-12-31 2021-10-20 BioAtla, Inc. Express humanization of antibodies
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
RU2495933C2 (ru) * 2011-05-30 2013-10-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ РОДА Escherichia ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА (ТАП) ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ) ИЛИ [-1]МЕТИОНИЛ-ФРАГМЕНТ ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), СПОСОБ ПОЛУЧЕНИЯ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ)
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CA2865614A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
WO2013177287A1 (en) * 2012-05-22 2013-11-28 Georgia Regents University Methods and vectors for gene targeting with inducible specific expression
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
CN103864913A (zh) 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
EP2958585A1 (en) 2013-02-22 2015-12-30 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US11013917B2 (en) 2013-06-21 2021-05-25 Newsouth Innovations Pty Limited Method and apparatus for close-field electroporation
US11306328B2 (en) * 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
EP3226889A4 (en) 2014-11-19 2018-11-21 The Trustees of Columbia University in the City of New York Osteocalcin as a treatment for frailty associated with aging
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP2018535692A (ja) 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
ES2892972T3 (es) 2015-11-02 2022-02-07 Univ Texas Métodos de activación de CD40 y bloqueo de punto de control inmunitario
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
EP3484911B1 (en) 2016-07-15 2020-11-04 H. Hoffnabb-La Roche Ag Method for purifying pegylated erythropoietin
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
AU2017337147A1 (en) 2016-09-30 2019-03-21 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
MX2019003983A (es) 2016-10-06 2019-06-10 Poseida Therapeutics Inc Caspasas inducibles y metodos de uso.
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
KR20190124304A (ko) 2017-03-13 2019-11-04 포세이다 테라퓨틱스, 인크. 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019108733A2 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
ES2905105T3 (es) 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
CN111741770A (zh) 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
CA3092947A1 (en) 2018-03-07 2019-09-12 Poseida Therapeutics, Inc. Cartyrin compositions and methods for use
US11225516B2 (en) 2018-04-20 2022-01-18 Janssen Biotech, Inc. Transition analysis method for chromatography column qualification
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CA3160103A1 (en) 2018-09-24 2020-04-02 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
US20220042038A1 (en) 2018-12-20 2022-02-10 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
CA3126654A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
MX2021008871A (es) 2019-01-23 2021-08-19 Janssen Biotech Inc Composiciones de anticuerpos anti-tnf para usarse en metodos para el tratamiento de la artritis psoriasica.
US20220153829A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
CA3133395A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CN113853385A (zh) 2019-03-18 2021-12-28 詹森生物科技公司 用抗il12/il23抗体治疗儿科受试者的银屑病的方法
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US20220306727A1 (en) 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
KR20220057596A (ko) 2019-09-05 2022-05-09 포세이다 테라퓨틱스, 인크. 동종이계 세포 조성물 및 사용 방법
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
KR20220149588A (ko) 2020-03-04 2022-11-08 포세이다 테라퓨틱스, 인크. 대사성 간 장애의 치료를 위한 조성물 및 방법
EP4118107A1 (en) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CA3174777A1 (en) 2020-04-14 2021-10-21 Eric M. Ostertag Compositions and methods for use in the treatment of cancer
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2022182797A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
KR20230148824A (ko) 2021-02-23 2023-10-25 포세이다 테라퓨틱스, 인크. 핵산을 전달하기 위한 조성물 및 방법
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
US20220298236A1 (en) 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023060089A2 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposases and uses thereof
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
IE56716B1 (en) * 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4822736A (en) * 1984-07-05 1989-04-18 Baylor College Of Medicine Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
EP0236059B1 (en) * 1986-02-27 1994-04-27 Snow Brand Milk Products Co. Ltd. Preparation of erythropoietin-producing cells and production process of erythropoietin using same
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
PT87363B (pt) * 1987-05-01 1993-11-30 Gen Hospital Corp Metodo para alterar a concentracao de um produto genetico
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
WO1991000361A1 (en) * 1989-06-23 1991-01-10 The United States Of America, Represented By The Secretary, United States Department Of Commerce Efficient method for identifiable expression of non-selectable genes
DK0452484T3 (da) * 1989-11-06 1996-10-14 Cell Genesys Inc Fremstilling af proteiner ved homolog rekombination
KR0176693B1 (ko) * 1989-12-22 1999-04-01 레지널드 디. 쇼트보그; 제롬 반 쥘렌 조절요소를 사용한 내인성 유전자의 발현을 변형시키는 방법
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
JPH04505710A (ja) * 1990-02-22 1992-10-08 ファーミング　ビーブイ ポリペプチドの改良された発現
IT1241123B (it) * 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP0535144A4 (en) * 1990-06-12 1993-08-11 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
WO1992003917A1 (en) * 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
DE69128037T2 (de) * 1990-11-13 1998-05-07 Immunex Corp Bifunktionelle wählbare fusionsgene
ES2132116T3 (es) * 1990-12-07 1999-08-16 Univ Florida Celulas recombinantes que expresan altamente genes heterologos cromosomicamente integrados.
SG93780A1 (en) * 1991-05-06 2003-01-21 Cell Genesys Inc Gene manipulation and expression using genomic elements
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
AU2515992A (en) * 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
NZ285945A (en) 1998-03-25
KR100379356B1 (ko) 2003-06-09
KR970703429A (ko) 1997-07-03
BR9507874A (pt) 1997-08-19
EP0759082A1 (en) 1997-02-26
RU2267533C2 (ru) 2006-01-10
CZ325896A3 (en) 1997-12-17
ZA953879B (en) 1996-01-18
JPH10500570A (ja) 1998-01-20
MX9605542A (es) 1998-05-31
AU709058B2 (en) 1999-08-19
NO964802D0 (no) 1996-11-12
IL113708A0 (en) 1995-08-31
SK146196A3 (en) 1998-02-04
FI964536A0 (fi) 1996-11-12
UA34493C2 (uk) 2001-03-15
CA2190289A1 (en) 1995-11-23
US5641670A (en) 1997-06-24
AU2550495A (en) 1995-12-05
CZ295115B6 (cs) 2005-05-18
WO1995031560A1 (en) 1995-11-23
HUT76844A (en) 1997-11-28
HU9603144D0 (en) 1997-01-28
FI964536A (fi) 1997-01-09

Similar Documents

Publication Publication Date Title
NO964802D0 (no) DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav
DE69632451D1 (de) Zange
DE69618599T2 (de) Ausnehmer
DE69423747D1 (de) Elektrisches heizgerät
NO964628D0 (no) DNA-sekvenser
HUT77108A (hu) DNS-szekvenciák és alkalmazásuk
DE69532874D1 (de) RPDL Protein und kodierende DNS
DE59505759D1 (de) Binderrücken
NO963474D0 (no) Oppvarmingssystem
DE69532881D1 (de) Ecdn - protein und dafuer kodeierende dna
DE9415089U1 (de) Zentralheizungsanlage
ATA77694A (de) Heizungsanlage
DE9404428U1 (de) Solarsterilisator
DE9415434U1 (de) Transportable Heizvorrichtung
DE69724736D1 (de) Prozessablaufsteuerung
DE29610994U1 (de) Reduzierstück
KR950032371U (ko) 가열용 지지대
DE69519715T2 (de) PRLTS-Proteine und die dafür kodierende DNA
DE29512132U1 (de) Heizungsanlage
DE9421712U1 (de) Heizsystem
GB2335193B (en) Rainbow trout ILβ; encoding nucleic acid; materials and methods
DE29520831U1 (de) Scherenheizgerät
KR980000165U (ko) 전기 훈증기용 히터
FI951693A0 (fi) Centralt dammsugarsystem
KR960000043U (ko) 온실용 보온재

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application